The subvariant accounted for 27.6 percent of U.S. COVID-19 cases in the week ending Jan. 7, up from 18.3 percent the week prior, CDC estimates show.
The Northeast has the highest proportion of cases from XBB.1.5 — sitting at more than 70 percent — while states in the Midwest have the lowest at about 5 percent.
Below is a breakdown of the subvariant’s prevalence in each HHS surveillance region as of Jan. 6:
|
HHS surveillance region |
Prevalence of XBB.1.5 |
|
Region 1 Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island and Vermont |
71.6 percent of all COVID-19 cases |
|
Region 2 New Jersey, New York, Puerto Rico and the Virgin Islands |
72.7 |
|
Region 3 Delaware, District of Columbia, Maryland, Pennsylvania, Virginia and West Virginia |
32.1 |
|
Region 4 Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina and Tennessee |
17.3 |
|
Region 5 Illinois, Indiana, Michigan, Minnesota, Ohio and Wisconsin |
7.3 |
|
Region 6 Arkansas, Louisiana, New Mexico, Oklahoma and Texas |
16.6 |
|
Region 7 Iowa, Kansas, Missouri and Nebraska |
5.6 |
|
Region 8 Colorado, Montana, North Dakota, South Dakota, Utah and Wyoming |
6.6 |
|
Region 9 Arizona, California, Hawaii, Nevada, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands and Republic of Palau |
7.6 |
|
Region 10 Alaska, Idaho, Oregon and Washington |
6.7 |
For more information on XBB.1.5’s transmissibility and severity, click here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
